Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEACE 7 darolutamide and stereotactic dose-escalated radiotherapy in high-risk localized prostate cancer
2023-509787-15-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Feb 2025
- Modality
- Small Molecules, Peptides, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of darolutamide and triptorelin in prostate cancer (PCa) (4 arms), sponsored by Unicancer. Primary endpoint: Metastasis-free survival. Planned start Feb 2025; status: authorised.
02
Drugs
darolutamidetriptorelin
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2023-509787-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509787-15-00.